MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2023 International Congress

    Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model

    C. Mo, Y. Qian, Y. Zhang, X. He, Y. Lai, S. Xu, P. Ai, X. Yang, Q. Xiao (Shanghai, China)

    Objective: To explore the effects of probiotics strains Bifidobacterium animalis subsp. lactis (B.lactis) and Lactobacillus acidophilus (L.acidophilus) on the inflammation of gut-brain axis and degeneration…
  • 2023 International Congress

    Potential genetic link between type I diabetes and Parkinson’s disease.

    K. Senkevich, P. Alipour, E. Chernyavskaya, E. Yu, A. Noyce, Z. Gan-Or (Montreal, Canada)

    Objective: To examine whether type 1 diabetes (T1D) is genetically or causally associated with Parkinson’s disease (PD). Background: Previous epidemiological and mendelian randomization studies demonstrated…
  • 2023 International Congress

    Hesperidin ameliorates rotenone-induced Parkinson’s disease in mice via improving neuroinflammation and oxidative stress

    D. Singh (Prayagraj, India)

    Objective: The goal of the present study is to examine the neuroprotective property of hesperidin on rotenone-induced Parkinson's disease in mice. Background: The second most…
  • 2023 International Congress

    The neuroprotective miRNA family hsa-miR-451 has a distinctive pattern of downregulation in neurodegenerative diseases.

    R. Singh, V. Swarup, I. Ahmad, V. Anand, I. Singh, M. Faruq, A. Srivastava (New Delhi, India)

    Objective: 1.Identification of microRNAs from whole blood PBMCs of SCA2 patients by using NGS.    2.To check the exclusivity of miRNAs in SCA2, SCA1,SCA3,SCA12,HD,ALS,PD and MSA-C…
  • 2022 International Congress

    Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease

    M. Sarswati, A. Gaur (Delhi, India)

    Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a  inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…
  • 2022 International Congress

    Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling

    D. Athauda, J. Evans, A. Wernick, G. Virdi, M. Choi, K. D'Sa, Z. Shadman, N. Greig, T. Foltynie, S. Gandhi (London, United Kingdom)

    Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…
  • 2022 International Congress

    Effect of CDNF in a novel combination stressor model of Parkinson’s disease

    A. Singh, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

    Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…
  • 2022 International Congress

    Effects of a novel neurotrophic compound in an animal model of Parkinson’s disease

    T. Viljakainen, M. Voutilainen (Helsinki, Finland)

    Objective: Investigate the neuroprotective effect of a novel compound in an animal model of Parkinson’s disease. Background: Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived…
  • 2022 International Congress

    Clove mediated Rescue in Parkinson’s Disease involves modulation of p53 and Sestrin2 in SHSY5Y cell line model

    N. Rai, S. Dey (Udaipur, India)

    Objective: The study analyzed the neuroprotective effect of ethanolic extract of clove against Parkinson’s disease (PD) type toxicity in SHSY5Y cell line model and interrogation…
  • 2022 International Congress

    Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)

    R. Kumar, D. Claassen, A. Mongan, A. Grover, B. Hoehn, P. Lin, R. Arnold, E. Cahir-Mcfarland, T. Yednock, S. Keswani (Englewood, USA)

    Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley